Solrikitug

BIOLOGICAL2 trials

Sponsors

NI One Inc., Uniquity One (UNI)

Conditions

Eosinophilic EsophagitisHealthy

Phase 1

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants

CompletedNCT06868082

Uniquity One (UNI)Healthy

Start: 2025-06-20End: 2026-02-02Updated: 2026-02-09

Phase 2

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study with an Extension to Investigate the Efficacy and Safety of Solrikitug in Adults with Eosinophilic Esophagitis (ALAMERE)

Active, not recruitingCTIS2024-510849-34-00

NI One Inc.Eosinophilic Esophagitis

Start: 2025-02-04Target: 49Updated: 2025-06-24